Skye Bioscience, Inc. Annual report pursuant to Section 13 and 15(d)

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2014

	As of December 31,
	2014			2013
Current deferred tax assets/(liabilities):
Capitalized research and development costs	$	25,265		$	-
Other		10,314			-
Net operating loss		989,544			-
Gross deferred tax assets		1,025,123			-
Valuation allowance		(1,025,123	)		-
Total deferred tax assets	$	-		$	-